Carlton Hogan

Suggest Changes
Learn More
In most clinical trials of antiretroviral therapy for patients infected with HIV, the major outcome variable has been the combined clinical endpoint of any new or recurrent AIDS defining event. We(More)
In 1994, Carlton Hogan testified before an FDA Antiviral Advisory Committee about the risks of letting drugs loose in the population without a rigorous method to detect and report late emerging(More)